TAONas-LUAD | Therapeutic Antisense Oligonucleotides Targeting NUMB Alternative Splicing in Lung Adenocarcinoma

Summary
Lung cancer is the leading cause of cancer-related deaths, with 1.8 million deaths expected globally in 2021. Lung adenocarcinomas (LUAD) represent 1/3 of all lung cancer cases. Despite notable advances, current treatments remain ineffective, resulting in
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/101058055
Start date: 01-04-2022
End date: 31-12-2025
Total budget - Public funding: 2 899 553,25 Euro - 2 899 553,00 Euro
Cordis data

Original description

Lung cancer is the leading cause of cancer-related deaths, with 1.8 million deaths expected globally in 2021. Lung adenocarcinomas (LUAD) represent 1/3 of all lung cancer cases. Despite notable advances, current treatments remain ineffective, resulting in

Status

SIGNED

Call topic

HORIZON-EIC-2021-TRANSITIONOPEN-01

Update Date

09-02-2023
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon Europe
HORIZON.3 Innovative Europe
HORIZON.3.1 The European Innovation Council (EIC)
HORIZON.3.1.0 Cross-cutting call topics
HORIZON-EIC-2021-TRANSITIONOPEN-01 EIC Transition Open 2021